Iannitto E, Ferrero S, Bommier C, Drandi D, et al. Erratum to: Bendamustine and rituximab as first-line treatment for symptomatic splenic marginal zone lymphoma: long-term outcome and impact of early unmeasurable minimal residual disease attainment from the BRISMA/IELSG36 phase II study. Haematologica 2025;110:1048-1049.
PMID: 40165734